Gastroenterology

Phase 3 KEPLER data showed vedolizumab achieved remission in nearly half of children with ulcerative colitis, with consistent safety and durable benefit.

GLP-1 receptor agonist use was associated with a lower risk of asthma exacerbations in adolescents with overweight or obesity.

Dupilumab maintained histologic and endoscopic improvements across all pediatric age groups with EoE, according to Joshua Wechsler, MD.

Can you guess the diagnosis?

Fifteen infants with suspected or confirmed infant botulism and a confirmed exposure to Byheart Whole Nutrition infant formula have been reported from 12 states.

Thomas Wallach, MD, discusses phase 3 safety data of tenapanor in pediatric patients with IBS-C, presented at the 2025 NASPGHAN Annual Meeting.

Long-term analysis of the PEDFIC studies presented at NASPGHAN 2025 demonstrated sustained reductions in bile acids and pruritus with odevixibat in FIC1 deficiency.

At NASPGHAN 2025, investigators presented 52-week safety data from an ongoing phase 3 trial of linaclotide, the first approved treatment for patients aged 7 and older with IBS-C.

FDA approves first irritable bowel syndrome with constipation (IBS-C) treatment, linaclotide (Linzess), for children aged 7 years and older based on pediatric and adult trial data.

If approved, this UC indication would add to pediatric indications of ustekinumab for psoriasis and active psoriatic arthritis.

Decline in maternal smoking linked to fewer US newborns with gastroschisis, highlighting benefits of public health efforts.

Pediatricians play a crucial role in preventing early-onset colorectal cancer by promoting healthy diets and fiber intake among children.

The revised labeling will warn that patients younger than 6 years taking these medications are at greater risk of weight loss.

Though the decision will not meet the June 17, 2025, target date, the federal agency anticipates a decision within approximately 4 weeks.

Colleen Sloan, PA-C, RDN, highlights the connection between poor dietary patterns and mental health challenges in children, and offers nutrient-focused solutions.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Colleen Sloan, PA-C, RDN, highlights what she is seeing in practice related to screen time, devices, and social media and impacts on nutrition.

According to the agency, it is seeking public input to "determine whether existing nutrient requirements should be revised based on latest scientific data."

Maternal avocado consumption during pregnancy was linked to significantly lower odds of infant food allergy at 12 months.

In this article, we recap our top stories, expert interviews, and Q+A discussions from the 2025 Pediatric Academic Societies meeting.

New research led by Geetika Kennady, MD, FAAP, showed that 10.6% of newborns have iron deficiency, supporting a push for earlier screening.

One step will be a partnership with the National Institutes of Health to research how food additives impact children's health.

"We are getting away from biopsies to diagnose CD, which makes diagnosis even easier, said Jon Matthew Farber, MD.

Breastfeeding for 6 months was linked to fewer developmental delays and neurodevelopmental conditions, supporting current recommendations.

In the United States, maralixibat (Livmarli; Mirum Pharmaceuticals) is approved to treat both ALGS and PFIC, now in liquid and tablet formulations.